This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Liquid Biopsy Market

Market Insights on Liquid Biopsy covering sales outlook, demand forecast & up-to-date key trends

Liquid Biopsy Market by Marker Type (CTCs (Circulating Tumour Cells), ctNA (Circulating tumor Nucleic Acids), Exosomes), Sample Type (Blood, Urine, Others (Plasma, Saliva, CSF)), Application Type (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer), End User & Region - Forecast to 2021 - 2031

Liquid Biopsy Market Snapshot

[262 Pages Report] As per a recent market analysis by ESOMAR-certified firm Future Market Insights (FMI), the global Liquid Biopsy Market value is pegged to reach US$ 1,026 Mn in 2021. Rising at 13.49% CAGR the market is expected to total US$ 3,637 Mn by 2031.

Cost-effectiveness and high efficacy of liquid biopsy over other diagnostic tests are chief factors responsible for market growth. Fast track approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for non-invasive cancer diagnosis tests will continue creating growth opportunities.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Liquid Biopsy Market Survey

  • Market estimates and forecast 2021-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Liquid Biopsy Market and how to Navigate
  • Recommendation on Key Winning Strategies

Liquid Biopsy Market Historic Sales Compared to 2021-2031 Forecast Outlook

Owing to rising incidence of cancer across the globe, several biotech companies were compelled to roll out highly efficient and innovative diagnostic tests, which led to expansions in the global liquid biopsy market. As per FMI’s recent study, the market reached a valuation of US$ 1,194 Mn in 2019, expanding at an impressive 19.68% CAGR between 2016 and 2020.

Liquid Biopsy Market Download Report Brochure

In 2020, the advent of the coronavirus outbreak led to interruptions in development of liquid biopsy tests. The focus was actively shifted to development of vaccines for COVID-19, and most clinical appointments were put on hold. These factors briefly affected the growth of liquid biopsy market, resulting in a decline in sales.

However, FMI projects a positive growth outlook for the liquid biopsy market through 2031. Increasing innovations in molecular diagnostic tests will provide tailwinds to the market sales. The preference for non-invasive diagnostic procedures will lead to significant adoption of liquid biopsy tests among oncologists, which will further augment growth.

What is the Impact of COVID-19 on Liquid Biopsy Market?

Research based on cancer diagnostics and treatment has been at the forefront of ushering transformation in the medical industry for several years. However, with the outbreak of COVID-19, research activities went on hold and the focus shifted on deriving measures to contain the novel coronavirus.

Primarily, sales of diagnostic equipment and other medications were mildly affected, but liquid biopsy still held its ground. The unprecedented events delayed several surgical procedures and endoscopies, with a drop in urgent treatment referrals. This trend engulfed liquid biopsy procedures as well, as most procedures were rescheduled, impacting the sales.

Irrespective of the pandemic, cancer cases were on the rise, which made diagnostic procedures imperative. For developing faster and more accurate diagnostic processes, governmental policies and intensive research and development increased in 2020, and the trend is expected to continue throughout the assessment period.

In addition, rapid technological advancements will facilitate the development of faster and more convenient liquid biopsy procedures, shaping the demand outlook positively. To curb the global burden of cancer, key players are launching simpler and effective liquid biopsy technologies and procedures. Thereby, widening lucrative growth opportunities over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How will Government Initiatives Aid Liquid Biopsy Market Growth?

Cancer has been affecting humanity for decades, and the numbers continue to rise even with the emergence of better treatment and care. In 2020, the World Health Organization (WHO) reported nearly 10 million deaths caused due to cancer. This staggering rise in number emphasizes on the need for accurate and convenient cancer diagnostic systems for early detection.

Governments in various high cancer burden nations have pledged to assist cancer research by providing adequate funds that can aid improved outcomes. For instance, as per the National Institute of Health (NIH), the federal government has allocated US$ 119 Mn to National Cancer Institute for the fiscal year 2021.

Similarly, in 2018, India-UK Cancer Research Initiative came into effect which focused on improved and affordable approaches to cancer diagnosis and treatment. The initiative will receive investments valued at £5 Mn from the Department of Biotechnology (DBT), Ministry of Science & Technology, India, and Cancer Research UK (CRUK) each over a 5-year program.

These government-led initiatives will further promote cancer specialists across the globe to set research goals aimed at affordability, convenience, and optimal patient care in cancer treatments. Adequate funding will allow experts to develop research alliances to enable significant improvements against numerous cancer outcomes.

Liquid Biopsy to be More Preferred over Traditional Biopsy Procedures

Owing to non-invasiveness and comparatively affordable price, liquid biopsy procedures are gaining immense traction in medical research and cancer treatment. Liquid biopsy procedures are primarily used for diagnosing breast cancer, leukemia, and lung cancer, which are the most prevalent forms of cancer.

In recent years, liquid biopsy is largely being preferred by cancer institutes, hospitals, and research centers for obtaining accurate results. These procedures assess cancer genetic status by analyzing circulating biomarkers that are present in the blood and enable early cancer detection and monitor reoccurrence of tumors during treatment.

Besides this, liquid biopsy can potentially detect tumor formation in its nascent stage, asses multiple tumor mutations, and effectively monitor the treatment process. These factors are making liquid biopsy one of the most preferred diagnostic measures in oncology, and the trend is projected to continue during the upcoming years.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Next Generation Liquid Biopsy Approaches to Remain Highly Sought-after

With the ongoing technological advancements in cancer research, next-generation liquid biopsy approaches are applying deeper and broader gene sequencing to derive both tumor and non-tumor-based cancer signals.

Deeper gene sequencing helps researchers identify a wealth of cancer markers in the blood circulation and circulating tumor DNA (ctDNA), resulting in implementation of data-science-driven liquid biopsies in oncology. The shift of liquid biopsies from digital mutation signals to analog signals is opening pathways for machine learning incorporation.

In addition to machine learning, rapid technological innovations in liquid biopsy have also driven the production of increasingly sensitive microchip-based technologies. These microchips are highly specific in nature and can potentially measure increasing numbers of biomarkers while being clinically deployable.

Advent of these algorithmic technologies has actively facilitated developments in liquid biopsy procedures, aiding diagnosis, prediction, and medical decision making.

Country-wise Insights

How will the Liquid Biopsy Market Expand in the U.S.?

As per FMI’s analysis, the U.S. is projected to account for 51% of the total market share in the liquid biopsy market during the assessment period. Growth prospects in the U.S. can be attributed to increasing government funding to support cancer research. Rising prevalence of cancer across the U.S. will generate high demand for highly accurate liquid biopsy services.

Wide adoption of technological developments including artificial intelligence, machine learning, and microchip-based liquid biopsy diagnostic services will lead market expansion in the U.S.

In addition to this, presence of major players including Biocept Inc., Janssen Global Services, and Trovagene Inc., will further lead to innovation in liquid biopsy technologies and procedures. Thereby, creating remunerative opportunities in liquid biopsy market. 

What is the Scope of Liquid Biopsy Market Growth in The U.K.?

As per report by Macmillan Cancer Support, the number of cancer patients is estimated to reach 4 million by 2030. Foreseeable spike in cancer cases will underscore the need for liquid biopsy to actively diagnose patients for early treatment and care.

The presence of several well-known research institutes in the U.K. such as the University of Oxford and the National Institute of Medical Research will further lead to developments in liquid biopsy services.

These developments will provide lucrative opportunities for players operating in the market, allowing them to benefit from technological advancements for better products and services. The U.K. will account for 24% of the market share, as estimated by FMI.

How will Japan Emerge as A Lucrative Market?

As per a recent report by the Japan Agency of Medical Research and Development, the country has launched ‘CIRCULATE-Japan’, a research project to analyze cancer treatments through liquid biopsy for testing circulating tumor DNA in the blood of patients suffering from colorectal cancer.

The research project is mainly launched to derive the clinical advantages of risk assessment

of tumors through liquid biopsy for ‘invisible cancers’.

With increasing incidence of cancer in the country, it focus on developing convenient and accurate diagnosis procedures is on the rise. These trends are anticipated to provide tailwinds to demand for liquid biopsy services as a ripple effect.

What Are the Growth Prospects for Liquid Biopsy Market in India?

Government initiatives aimed at improving cancer awareness, research, and development are anticipated to propel growth of liquid biopsy market in India, as per FMI's market survey.

As revealed by the National Cancer Registry, cancer incidence in men is estimated to reach 736,575 in 2025, with 806,218 cases to be recorded in women.

Increasing number of cancer cases is anticipated to underscore the pressing need for technologically advanced liquid biopsy systems, which in turn will shape the demand outlook in the country.

Additionally, numerous budding and established biotech companies in India are focusing on research and development for early diagnosis and improvements in cancer treatment and patient care.

Such developments will provide opportunities for market expansion to major global players, thereby propelling sales in India.

Category-wise Insights

Why Are Circulating Tumor Cells (CTC) More Preferred? 

As per FMI's analysis, based on markers, circulating tumor cells (CTCs) are anticipated to witness lucrative growth during the assessment period.

CTCs are primarily found in the blood, urine and other bodily fluids of cancer patients and elevated levels suggest the onset of cancer. These markers adequately detect prognosis, factors suggesting residual disease, and monitor the effectiveness of treatment.

Non-invasiveness of CTC marker detection through urine and saliva is a chief factor highlighting the significance of CTC markers in oncology, leading to increased adoption of CTC-based liquid biopsy.

Blood Samples Will Lead the Sample Type Segment 

Based on sample type, blood samples will be accepted widely in liquid biopsy procedures. Circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) are two common elements that are targeted in liquid biopsy procedures.

To detect these elements, a simple blood sample is required. Most patients are comfortable with taking blood samples as they are non-stressful and involve minimal pain, more like a pricking sensation.

Blood samples are also useful when locating a tumor and removing a sample for diagnosis becomes difficult for oncologists. Blood sample collection is generally minimally invasive, making them the most widely preferred method of sample collection.

Rising Lung Cancer Cases Set To Propel Liquid Biopsy Applications 

The American Cancer Society’s reports estimate around 235,760 new cases of lung cancer (119,100 in men and 116,660 in women) in 2021. The alarming rise in lung cancer cases will press upon the need for effective liquid biopsies. 

As per FMI, liquid biopsy will find most.

Owing to high risk involved in these procedures, oncologists are preferring liquid biopsies over tumor biopsies in lung cancer patients. Liquid biopsies can potentially detect any genomic alterations in the circulating tumor cells (CTC) and guide oncologists towards required treatment options.

Cancer Institutes to Remain Dominant? 

By end-user, liquid biopsy will be widely applied in cancer institutes, accounting for 4/10th of the revenue share, followed by hospitals and diagnostic centers during the assessment period.

Increasing government initiatives for advanced cancer research are anticipated to boost liquid biopsy procedures in cancer institutes. Research and development aimed at better cancer treatment will generate the demand for liquid biopsy kits in cancer institutes, which in turn will promote sales.

Hospitals and diagnostic centers will follow suit, owing to on-site sample collection, diagnosis, and treatment.  

Competitive Landscape

Key players in the liquid biopsy market are aiming at strategic collaborations with end-users including hospitals, diagnostic centers, and cancer research institutes to strengthen their product offerings in the market. As per FMI analysis, tier-1 players will account for approximately 20-25% of the total sales.

Industry research funding and product development agreements will provide proprietary benefits to manufacturers, helping them contribute to the development of accurate diagnosis methods for various cancers. In addition, gaining patents and government approvals for new technologies will remain one of the prominent growth strategies. For instance:

  • In July 2021, Biocept Inc., one of the leading providers of molecular diagnostic services, received a South Korean Patent for its newly launched Primer-Switch technology. Primer-Switch technology detects mutations in circulating tumor DNA (ctDNA) using real-time PCR and related methods, identifying rare cancer biomarkers.
  • In July 2021, Janssen Global Services, LLC, received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone (Pd) for treating adult patients with multiple myeloma, further strengthening the company’s product offerings.

Scope of Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD Million for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Key Segments Covered

Marker Type, Sample Type, Application Type, End-Users, and Regions

Key Companies Profiled

  • BIOCEPT, INC.
  • Qiagen N.V.
  • Trovagene, Inc
  • Janssen Global Services, LLC
  • MDxHealth SA
  • Natera, Inc
  • F. Hoffmann-La Roche Ltd
  • Silicon Biosystems
  • Pathway Genomics Corporation
  • Sysmex Corporation

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Liquid Biopsy Market by Category

By Marker Type:

  • CTCs (Circulating Tumour Cells)
  • ctNA (Circulating tumor Nucleic Acids)
  • Exosomes

By Sample Type:

  • Blood
  • Urine
  • Others (Plasma, Saliva, CSF)

By Application Type:

  • Lung Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia

By End-Users:

  • Hospitals
  • Cancer Institutes
  • Academic Institutes
  • Diagnostic Centers

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East & Africa

Frequently Asked Questions

Currently, the liquid biopsy market is valued at US$ 1,026 Mn.

The liquid biopsy market experienced impressive growth, exhibiting a 19.68% CAGR.

Increasing demand from biotech and pharmaceutical companies, coupled with leading players launching innovation molecular diagnostics tests are prominent trends driving liquid biopsy sales.

North America’s liquid biopsy market will account for approximately 51% of the global market share between 2021-2031.

The top 5 players in the liquid biopsy market are anticipated to account for around 20-25% of the total sales.

The U.K. will account for 24% of the global liquid biopsy market in Europe.

Top countries driving liquid biopsy sales are the U.S., Canada, the U.K., Germany and China.

South Korea and Japan will collectively account for 4.5% of the global liquid biopsy market share.

Table of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Liquid Biopsy Market Overview

    4.1. Introduction

        4.1.1. Liquid Biopsy Market Definition

        4.1.2. Liquid Biopsy Market Taxonomy

    4.2. Liquid Biopsy Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Regional Cancer Epidemiology

    4.4. Reimbursement Scenario

    4.5. Pipeline Assessment, By Products 

    4.6. Product Penetration and Pricing Impact 

    4.7. Revenue Potential Liquid Biopsy 

    4.8. Case Studies

5. Global Liquid Biopsy Market Forecast

    5.1. Market Value (US$ Mn) Forecast

        5.1.1. Y-o-Y Growth Projections

        5.1.2. Absolute $ Opportunity

    5.2. Liquid Biopsy Market Trends

    5.3. Global Liquid Biopsy Market Snapshot (2015)

        5.3.1. Market Share, By Sample Type 

        5.3.2. Market Share, By Disease Indication 

        5.3.3. Market Share, By Marker Type 

        5.3.4. Market Share, By End User 

6. Global Liquid Biopsy Market Analysis, By Sample Type 

    6.1. Introduction

        6.1.1. Y-o-Y Growth Comparison, By Sample Type 

        6.1.2. Market Share & Basis Point (BPS) Analysis, By Sample Type 

    6.2. Market Forecast, By Sample Type 

        6.2.1. Blood 

            6.2.1.1. Absolute $ Opportunity

            6.2.1.2. Market Value (US$ Mn) Forecast

        6.2.2. Urine

            6.2.2.1. Absolute $ Opportunity

            6.2.2.2. Market Value (US$ Mn) Forecast

        6.2.3. Others (Plasma, Saliva, CSF)

            6.2.3.1. Absolute $ Opportunity

            6.2.3.2. Market Value (US$ Mn) Forecast

    6.3. Market Attractiveness Analysis, By Sample Type 

7. Global Liquid Biopsy Market Analysis, By Marker Type 

    7.1. Introduction

        7.1.1. Y-o-Y Growth Comparison, By Marker Type 

        7.1.2. Market Share & Basis Point (BPS) Analysis, By Marker Type 

    7.2. Market Forecast, By Marker Type 

        7.2.1. CTCs (circulating tumor cells)

            7.2.1.1. Absolute $ Opportunity

            7.2.1.2. Market Value (US$ Mn) Forecast

        7.2.2. ctNA (circulating tumor nucleic acids)

            7.2.2.1. Absolute $ Opportunity

            7.2.2.2. Market Value (US$ Mn) Forecast

        7.2.3. Exosomes

            7.2.3.1. Absolute $ Opportunity

            7.2.3.2. Market Value (US$ Mn) Forecast

    7.3. Market Attractiveness Analysis, By Marker Type 

8. Global Liquid Biopsy Market Analysis, By End User 

    8.1. Introduction

        8.1.1. Y-o-Y Growth Comparison, By End User 

        8.1.2. Market Share & Basis Point (BPS) Analysis, By End User 

    8.2. Market Forecast, By End User 

        8.2.1. Hospitals 

            8.2.1.1. Absolute $ Opportunity

            8.2.1.2. Market Value (US$ Mn) Forecast

        8.2.2. Academic Institutes 

            8.2.2.1. Absolute $ Opportunity

            8.2.2.2. Market Value (US$ Mn) Forecast

        8.2.3. Cancer Institutes 

            8.2.3.1. Absolute $ Opportunity

            8.2.3.2. Market Value (US$ Mn) Forecast

        8.2.4. Diagnostic Centers

            8.2.4.1. Absolute $ Opportunity

            8.2.4.2. Market Value (US$ Mn) Forecast

    8.3. Market Attractiveness Analysis, By End User 

9. Global Liquid Biopsy Market Analysis, By Disease Indication 

    9.1. Introduction

        9.1.1. Y-o-Y Growth Comparison, By Disease Indication 

        9.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication 

    9.2. Market Forecast, By Disease Indication 

        9.2.1. Lung Cancer 

            9.2.1.1. Absolute $ Opportunity

            9.2.1.2. Market Value (US$ Mn) Forecast

        9.2.2. Leukemia 

            9.2.2.1. Absolute $ Opportunity

            9.2.2.2. Market Value (US$ Mn) Forecast

        9.2.3. Gastrointestinal Cancer

            9.2.3.1. Absolute $ Opportunity

            9.2.3.2. Market Value (US$ Mn) Forecast

        9.2.4. Breast Cancer

            9.2.4.1. Absolute $ Opportunity

            9.2.4.2. Market Value (US$ Mn) Forecast

        9.2.5. Prostate Cancer

            9.2.5.1. Absolute $ Opportunity

            9.2.5.2. Market Value (US$ Mn) Forecast

        9.2.6. Colorectal Cancer

            9.2.6.1. Absolute $ Opportunity

            9.2.6.2. Market Value (US$ Mn) Forecast

        9.2.7. Others

            9.2.7.1. Absolute $ Opportunity

            9.2.7.2. Market Value (US$ Mn) Forecast

    9.3. Market Attractiveness Analysis, By Disease Indication 

10. Global Liquid Biopsy Market Analysis, By Region

    10.1. Introduction

        10.1.1. Y-o-Y Growth Projections, By Region

        10.1.2. Market Share & Basis Point (BPS) Analysis, By Region

    10.2. Market Forecast, By Region

        10.2.1. North America Market Value (US$ Mn) Forecast

        10.2.2. Latin America Market Value (US$ Mn) Forecast

        10.2.3. Western Europe Market Value (US$ Mn) Forecast

        10.2.4. Eastern Europe Market Value (US$ Mn) Forecast

        10.2.5. APEJ Market Value (US$ Mn) Forecast

        10.2.6. Japan Market Value (US$ Mn) Forecast

        10.2.7. Middle East and Africa Market Value (US$ Mn) Forecast

    10.3. Regional Attractiveness Analysis

11. North America Liquid Biopsy Market Analysis

    11.1. Introduction

        11.1.1. Y-o-Y Growth Projections, By Country

        11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    11.2. Key Trends

    11.3. North America Market Forecast

        11.3.1. Market Value (US$ Mn) Forecast, By Country

            11.3.1.1. U.S. Absolute $ Opportunity

            11.3.1.2. Canada Absolute $ Opportunity

        11.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            11.3.2.1. Blood 

            11.3.2.2. Urine

            11.3.2.3. Others (Plasma, Saliva, CSF)

        11.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

            11.3.3.1. CTCs (circulating tumor cells)

            11.3.3.2. ctNA (circulating tumor nucleic acids)

            11.3.3.3. Exosomes

        11.3.4. Market Value (US$ Mn) Forecast, By End User 

            11.3.4.1. Hospitals 

            11.3.4.2. Academic Institutes 

            11.3.4.3. Cancer Institutes 

            11.3.4.4. Diagnostic Centers

        11.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

            11.3.5.1. Lung Cancer 

            11.3.5.2. Leukemia 

            11.3.5.3. Gastrointestinal Cancer

            11.3.5.4. Breast Cancer

            11.3.5.5. Prostate Cancer

            11.3.5.6. Colorectal Cancer

            11.3.5.7. Others

    11.4. Market Attractiveness Analysis

           11.4.1. By Country

           11.4.2. By Sample Type 

           11.4.3. By Disease Indication 

           11.4.4. By Marker Type 

           11.4.5. By End User 

    11.5. Drivers & Restraints: Impact Analysis

12. Latin America Liquid Biopsy Market Analysis

    12.1. Introduction

        12.1.1. Y-o-Y Growth Projections, By Country

        12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    12.2. Key Trends

    12.3. Latin America Market Forecast

        12.3.1. Market Value (US$ Mn) Forecast, By Country

            12.3.1.1. Brazil Absolute $ Opportunity

            12.3.1.2. Mexico Absolute $ Opportunity

            12.3.1.3. Rest of Latin America Absolute $ Opportunity

        12.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            12.3.2.1. Blood 

            12.3.2.2. Urine

            12.3.2.3. Others (Plasma, Saliva, CSF)

        12.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

            12.3.3.1. CTCs (circulating tumor cells)

            12.3.3.2. ctNA (circulating tumor nucleic acids)

            12.3.3.3. Exosomes 

        12.3.4. Market Value (US$ Mn) Forecast, By End User 

            12.3.4.1. Hospitals 

            12.3.4.2. Academic Institutes 

            12.3.4.3. Cancer Institutes 

            12.3.4.4. Diagnostic Centers

        12.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

            12.3.5.1. Lung Cancer 

            12.3.5.2. Leukemia 

            12.3.5.3. Gastrointestinal Cancer

            12.3.5.4. Breast Cancer

            12.3.5.5. Prostate Cancer

            12.3.5.6. Colorectal Cancer

            12.3.5.7. Others

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Sample Type 

        12.4.3. By Disease Indication 

        12.4.4. By Marker Type 

        12.4.5. By End User 

    12.5. Drivers & Restraints: Impact Analysis

13. Western Europe Liquid Biopsy Market Analysis

    13.1. Introduction

        13.1.1. Y-o-Y Growth Projections, By Country

        13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    13.2. Key Trends

    13.3. Western Europe Market Forecast

        13.3.1. Market Value (US$ Mn) Forecast, By Country

            13.3.1.1. Germany Absolute $ Opportunity

            13.3.1.2. France Absolute $ Opportunity

            13.3.1.3. U.K. Absolute $ Opportunity

            13.3.1.4. Spain Absolute $ Opportunity

            13.3.1.5. Italy Absolute $ Opportunity

            13.3.1.6. Rest of Western Europe Absolute $ Opportunity

        13.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            13.3.2.1. Blood 

            13.3.2.2. Urine

            13.3.2.3. Others (Plasma, Saliva, CSF)

        13.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

            13.3.3.1. CTCs (circulating tumor cells)

            13.3.3.2. ctNA (circulating tumor nucleic acids)

            13.3.3.3. Exosomes

        13.3.4. Market Value (US$ Mn) Forecast, By End User 

            13.3.4.1. Hospitals 

            13.3.4.2. Academic Institutes 

            13.3.4.3. Cancer Institutes 

            13.3.4.4. Diagnostic Centers

        13.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

            13.3.5.1. Lung Cancer 

            13.3.5.2. Leukemia 

            13.3.5.3. Gastrointestinal Cancer

            13.3.5.4. Breast Cancer

            13.3.5.5. Prostate Cancer

            13.3.5.6. Colorectal Cancer

            13.3.5.7. Others

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Sample Type 

        13.4.3. By Disease Indication 

        13.4.4. By Marker Type 

        13.4.5. By End User 

    13.5. Drivers & Restraints: Impact Analysis

14. Eastern Europe Liquid Biopsy Market Analysis

    14.1. Introduction

        14.1.1. Y-o-Y Growth Projections, By Country

        14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    14.2. Key Trends

    14.3. Eastern Europe Market Forecast

        14.3.1. Market Value (US$ Mn) Forecast, By Country

            14.3.1.1. Russia Absolute $ Opportunity

            14.3.1.2. Poland Absolute $ Opportunity

            14.3.1.3. Rest of Eastern Europe Absolute $ Opportunity

        14.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            14.3.2.1. Blood 

            14.3.2.2. Urine

            14.3.2.3. Others (Plasma, Saliva, CSF)

        14.4.3. Market Value (US$ Mn) Forecast, By Marker Type 

            14.4.3.1. CTCs (circulating tumor cells)

            14.4.3.2. ctNA (circulating tumor nucleic acids)

            14.4.3.3. Exosomes

        14.4.4. Market Value (US$ Mn) Forecast, By End User 

           14.4.4.1. Hospitals 

           14.4.4.2. Academic Institutes 

           14.4.4.3. Cancer Institutes 

           14.4.4.4. Diagnostic Centers

        14.4.5. Market Value (US$ Mn) Forecast, By Disease Indication 

           14.4.5.1. Lung Cancer 

           14.4.5.2. Leukemia 

           14.4.5.3. Gastrointestinal Cancer

           14.4.5.4. Breast Cancer

           14.4.5.5. Prostate Cancer

           14.4.5.6. Colorectal Cancer

           14.4.5.7. Others

    14.5. Market Attractiveness Analysis

          14.5.1. By Country

          14.5.2. By Sample Type

          14.5.3. By Disease Indication 

          14.5.4. By Marker Type 

          14.5.5. By End User

15. APEJ Liquid Biopsy Market Analysis

    15.1. Introduction

        15.1.1. Y-o-Y Growth Projections, By Country

        15.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    15.2. Key Trends

    15.3. APEJ Market Forecast

        15.3.1. Market Value (US$ Mn) Forecast, By Country

            15.3.1.1. China Absolute $ Opportunity

            15.3.1.2. India Absolute $ Opportunity

            15.3.1.3. Australia & New Zealand Absolute $ Opportunity

            15.3.1.4. ASEAN Absolute $ Opportunity

            15.3.1.5. Rest of APEJ Absolute $ Opportunity

        15.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            15.3.2.1. Blood 

            15.3.2.2. Urine

            15.3.2.3. Others (Plasma, Saliva, CSF)

        15.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

           15.3.3.1. CTCs (circulating tumor cells)

           15.3.3.2. ctNA (circulating tumor nucleic acids)

           15.3.3.3. Exosomes

        15.3.4. Market Value (US$ Mn) Forecast, By End User 

           15.3.4.1. Hospitals 

           15.3.4.2. Academic Institutes 

           15.3.4.3. Cancer Institutes 

           15.3.4.4. Diagnostic Centers

        15.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

           15.3.5.1. Lung Cancer 

           15.3.5.2. Leukemia 

           15.3.5.3. Gastrointestinal Cancer

           15.3.5.4. Breast Cancer

           15.3.5.5. Prostate Cancer

           15.3.5.6. Colorectal Cancer

           15.3.5.7. Others

    15.4. Market Attractiveness Analysis

       15.4.1. By Country

       15.4.2. By Sample Type 

       15.4.3. By Disease Indication 

       15.4.4. By Marker Type 

       15.4.5. By End User 

    15.5. Drivers & Restraints: Impact Analysis

16. Japan Liquid Biopsy Market Analysis

    16.1. Introduction

    16.2. Key Trends

    16.3. Japan Market Forecast

        16.3.1. Market Value (US$ Mn) Forecast, By Sample Type 

            16.3.1.1. Blood 

            16.3.1.2. Urine

            16.3.1.3. Others (Plasma, Saliva, CSF)

        16.3.2. Market Value (US$ Mn) Forecast, By Marker Type 

            16.3.2.1. CTCs (circulating tumor cells)

            16.3.2.2. ctIndication (circulating tumor nucleic acids)

            16.3.2.3. Exosomes

        16.3.3. Market Value (US$ Mn) Forecast, By End User 

            16.3.3.1. Hospitals 

            16.3.3.2. Academic Institutes 

            16.3.3.3. Cancer Institutes 

            16.3.3.4. Diagnostic Centers

        16.3.4. Market Value (US$ Mn) Forecast, By Disease Indication 

            16.3.4.1. Lung Cancer 

            16.3.4.2. Leukemia 

            16.3.4.3. Gastrointestinal Cancer

            16.3.4.4. Metastatic Breast Cancer

            16.3.4.5. Metastatic Prostate Cancer

            16.3.4.6. Metastatic Colorectal Cancer

            16.3.4.7. Others

    16.4. Market Attractiveness Analysis

        16.4.1. By Sample Type 

        16.4.2. By Disease Indication 

        16.4.3. By Marker Type 

        16.4.4. By End User 

    16.5. Drivers & Restraints: Impact Analysis

17. Middle East and Africa Liquid Biopsy Market Analysis

    17.1. Introduction

        17.1.1. Y-o-Y Growth Projections, By Country

        17.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    17.2. Key Trends

    17.3. Middle East and Africa Market Forecast

        17.3.1. Market Value (US$ Mn) Forecast, By Country

            17.3.1.1. GCC Countries Absolute $ Opportunity

            17.3.1.2. South Africa Absolute $ Opportunity

            17.3.1.3. Rest of MEA Absolute $ Opportunity

        17.3.2. Market Value (US$ Mn) Forecast, By Sample Type 

            17.3.2.1. Blood 

            17.3.2.2. Urine

            17.3.2.3. Others (Plasma, Saliva, CSF)

        17.3.3. Market Value (US$ Mn) Forecast, By Marker Type 

            17.3.3.1. CTCs (circulating tumor cells)

            17.3.3.2. ctNA (circulating tumor nucleic acids)

            17.3.3.3. Exosomes

        17.3.4. Market Value (US$ Mn) Forecast, By End User 

            17.3.4.1. Hospitals 

            17.3.4.2. Academic Institutes 

            17.3.4.3. Cancer Institutes 

            17.3.4.4. Diagnostic Centers

        17.3.5. Market Value (US$ Mn) Forecast, By Disease Indication 

            17.3.5.1. Lung Cancer 

            17.3.5.2. Leukemia 

            17.3.5.3. Gastrointestinal Cancer

            17.3.5.4. Metastatic Breast Cancer

            17.3.5.5. Metastatic Prostate Cancer

            17.3.5.6. Metastatic Colorectal Cancer

            17.3.5.7. Others

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Sample Type 

        17.4.3. By Disease Indication 

        17.4.4. By Marker Type 

        17.4.5. By End User 

    17.5. Drivers & Restraints: Impact Analysis

18. Competition Landscape

    18.1. Competition Dashboard

    18.2. Company Profiles Inclusions

        18.2.1. Revenue

        18.2.2. Products/Brand Offerings

        18.2.3. Key developments

        18.2.4. SWOT Analysis

    18.3. Company Profiled

        18.3.1. BIOCEPT, INC.

            18.3.1.1. Revenue

            18.3.1.2. Products/Brand Offerings

            18.3.1.3. Key developments

            18.3.1.4. SWOT Analysis

        18.3.2. Qiagen N.V.

            18.3.2.1. Revenue

            18.3.2.2. Products/Brand Offerings

            18.3.2.3. Key developments

            18.3.2.4. SWOT Analysis

        18.3.3. Trovagene, Inc

            18.3.3.1. Revenue

            18.3.3.2. Products/Brand Offerings

            18.3.3.3. Key developments

            18.3.3.4. SWOT Analysis

        18.3.4. Janssen Global Services, LLC

            18.3.4.1. Revenue

            18.3.4.2. Products/Brand Offerings

            18.3.4.3. Key developments

            18.3.4.4. SWOT Analysis

        18.3.5. MDxHealth SA

            18.3.5.1. Revenue

            18.3.5.2. Products/Brand Offerings

            18.3.5.3. Key developments

            18.3.5.4. SWOT Analysis

        18.3.6. Natera, Inc

            18.3.6.1. Revenue

            18.3.6.2. Products/Brand Offerings

            18.3.6.3. Key developments

            18.3.6.4. SWOT Analysis

        18.3.7. F. Hoffmann-La Roche Ltd

            18.3.7.1. Revenue

            18.3.7.2. Products/Brand Offerings

            18.3.7.3. Key developments

            18.3.7.4. SWOT Analysis

        18.3.8. Silicon Biosystems

            18.3.8.1. Revenue

            18.3.8.2. Products/Brand Offerings

            18.3.8.3. Key developments

            18.3.8.4. SWOT Analysis

        18.3.9. Pathway Genomics Corporation

            18.3.9.1. Revenue

            18.3.9.2. Products/Brand Offerings

            18.3.9.3. Key developments

            18.3.9.4. SWOT Analysis

        18.3.10. Sysmex Corporation

            18.3.10.1. Revenue

            18.3.10.2. Products/Brand Offerings

            18.3.10.3. Key developments

            18.3.10.4. SWOT Analysi

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 02: Global Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 03: Global Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 04: Global Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 05: Global Liquid Biopsy Market Value Forecast By Region, 2021-2031

Table 06: North America Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 07: North America Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 08: North America Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 09: North America Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 10: North America Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 11: Latin America Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 12: Latin America Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 13: Latin America Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 14: Latin America Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 15: Latin America Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 16: Western Europe Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 17: Western Europe Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 18: Western Europe Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 19: Western Europe Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 20: Western Europe Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 21: Eastern Europe Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 22: Eastern Europe Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 23: Eastern Europe Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 24: Eastern Europe Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 25: Eastern Europe Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 26: APEJ Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 27: APEJ Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 28: APEJ Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 29: APEJ Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 30: APEJ Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 31: Japan Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 32: Japan Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 33: Japan Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 34: Japan Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Table 35: MEA Liquid Biopsy Market Value Forecast By Country, 2021-2031

Table 36: MEA Liquid Biopsy Market Value Forecast By Sample Type, 2021-2031

Table 37: MEA Liquid Biopsy Market Value Forecast By Marker Type, 2021-2031

Table 38: MEA Liquid Biopsy Market Value Forecast By End User, 2021-2031

Table 39: MEA Liquid Biopsy Market Value Forecast By Disease Indication, 2021-2031

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Liquid Biopsy Market Share Analysis (%) By Sample Type, 2021 & 2031

Figure 02: Global Liquid Biopsy Market Y-o-Y growth (%) By Sample Type, 2021-2031

Figure 03: Global Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 04: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Blood Sample Type Segment, 2021-2031

Figure 05: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Blood Sample Type Segment, 2021-2031

Figure 06: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Urine Sample Type Segment, 2021-2031

Figure 07: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Urine Sample Type Segment, 2021-2031

Figure 08: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2021-2031

Figure 09: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Others (Plasma, Saliva, CSF) Sample Type Segment, 2021-2031

Figure 10: Global Liquid Biopsy Market Share Analysis (%) By Marker Type, 2021 & 2031

Figure 11: Global Liquid Biopsy Market Y-o-Y growth (%) By Marker Type, 2021-2031

Figure 12: Global Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 13: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By CTCs Marker Type Segment, 2021-2031

Figure 14: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By CTCs Marker Type Segment, 2021-2031

Figure 15: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By CtNA Marker Type Segment, 2021-2031

Figure 16: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By ctNA Marker Type Segment, 2021-2031

Figure 17: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Exosomes Marker Type Segment, 2021-2031

Figure 18: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Exosomes Marker Type Segment, 2021-2031

Figure 19: Global Liquid Biopsy Market Share Analysis (%) By End User, 2021 & 2031

Figure 20: Global Liquid Biopsy Market Y-o-Y growth (%) By End User, 2021-2031

Figure 21: Global Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 22: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Hospitals End User Segment, 2021-2031

Figure 23: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2021-2031

Figure 24: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Cancer Institutes End User Segment, 2021-2031

Figure 25: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Cancer Institutes End User Segment, 2021-2031

Figure 26: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Academic Institutes End User Segment, 2021-2031

Figure 27: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Academic Institutes End User Segment, 2021-2031

Figure 28: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Diagnostics Centers End User Segment, 2021-2031

Figure 29: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Diagnostics Centers End User Segment, 2021-2031

Figure 30: Global Liquid Biopsy Market Share Analysis (%) By Disease Indication, 2021 & 2031

Figure 31: Global Liquid Biopsy Market Y-o-Y growth (%) By Disease Indication, 2021-2031

Figure 32: Global Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 33: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Lung Cancer Disease Indication Segment, 2021-2031

Figure 34: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Lung Cancer Disease Indication Segment, 2021-2031

Figure 35: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Gastrointestinal Cancer Disease Indication Segment, 2021-2031

Figure 36: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Gastrointestinal Cancer Disease Indication Segment, 2021-2031

Figure 37: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Prostate Cancer Disease Indication Segment, 2021-2031

Figure 38: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Prostate Cancer Disease Indication Segment, 2021-2031

Figure 39: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Breast Cancer Disease Indication Segment, 2021-2031

Figure 40: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Breast Cancer Disease Indication Segment, 2021-2031

Figure 41: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Colorectal Cancer Disease Indication Segment, 2021-2031

Figure 42: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Colorectal Cancer Disease Indication Segment, 2021-2031

Figure 43: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Leukemia Disease Indication Segment, 2021-2031

Figure 44: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Leukemia Disease Indication Segment, 2021-2031

Figure 45: Global Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%) By Others Cancer Disease Indication Segment, 2021-2031

Figure 46: Global Liquid Biopsy Market Absolute $ Opportunity (US$ Mn) By Others Cancer Disease Indication Segment, 2021-2031

Figure 47: Global Liquid Biopsy Market Share Analysis (%) By Region, 2021 & 2031

Figure 48: Global Liquid Biopsy Market Y-o-Y growth (%) By Region, 2021-2031

Figure 49: Global Liquid Biopsy Market Attractiveness Analysis By Region, 2021-2031

Figure 50: North America Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 51: North America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 53: Latin America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 54: Western Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 55: Western Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 56: Eastern Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 57: Eastern Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 58: APEJ Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 59: APEJ Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 60: Japan Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 61: Japan Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 62: MEA Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 63: MEA Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 64: North America Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 65: North America Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 66: North America Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 67: The U.S. Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 68: The U.S. Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 69: Canada Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 70: Canada Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 71: North America Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 72: North America Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 73: North America Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 74: North America Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 75: Latin America Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 76: Latin America Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 77: Latin America Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 78: Brazil Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 79: Brazil Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 80: Mexico Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 81: Mexico Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 82: Rest of Latin America Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 83: Rest of Latin America Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 84: Latin America Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 85: Latin America Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 86: Latin America Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 87: Latin America Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 90: Western Europe Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 91: Western Europe Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 92: Western Europe Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 93: The U.K Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 94: The U.K Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 95: Germany Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 96: Germany Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 97: France Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 98: France Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 99: Spain the liquid biopsy market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 100: Spain the liquid biopsy market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 101: Italy Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 102: Italy Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 103: NORDIC Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 104: NORDIC Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 105: BENELUX Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 106: BENELUX Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 107: Rest of Western Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 108: Rest of Western Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 109: Western Europe Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 110: Western Europe Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 111: Western Europe Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 112: Western Europe Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 113: Eastern Europe Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 114: Eastern Europe Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 115: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 116: Russia Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 117: Russia Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 118: Poland Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 119: Poland Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 120: Rest of Eastern Europe Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 121: Rest of Eastern Europe Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 122: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 123: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 124: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 125: Eastern Europe Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 126: APEJ Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 127: APEJ Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 128: APEJ Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 129: China Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 130: China Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 131: India Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 132: India Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 133: Australia & New Zealand Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 134: Australia & New Zealand Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 135: ASEAN Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 136: ASEAN Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 137: Rest of APEJ Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 138: Rest of APEJ Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 139: APEJ Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 140: APEJ Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 141: APEJ Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 142: APEJ Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 145: Japan Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 146: Japan Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Figure 143: Japan Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 144: Japan Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 147: MEA Liquid Biopsy Market Share Analysis (%) By Country, 2021 & 2031

Figure 148: MEA Liquid Biopsy Market Y-o-Y growth (%) By Country, 2021-2031

Figure 149: MEA Liquid Biopsy Market Attractiveness Analysis By Country, 2021-2031

Figure 150: GCC Countries Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 151: GCC Countries Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 152: South Africa Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 153: South Africa Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 154: Rest of MEA Liquid Biopsy Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 155: Rest of MEA Liquid Biopsy Market Absolute $ Opportunity (US$ Mn), 2021-2031

Figure 156: MEA Liquid Biopsy Market Attractiveness Analysis By Marker Type, 2021-2031

Figure 157: MEA Liquid Biopsy Market Attractiveness Analysis By End User, 2021-2031

Figure 158: MEA Liquid Biopsy Market Attractiveness Analysis By Sample Type, 2021-2031

Figure 159: MEA Liquid Biopsy Market Attractiveness Analysis By Disease Indication, 2021-2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Aspiration & Biopsy Needles Market

Published : February 2022

Healthcare

MRI Compatible Biopsy Devices Market

Published : August 2019

Healthcare

Lung Biopsy Systems Market

Published : April 2019

Healthcare

Breast Biopsy Device Market

Published : May 2016

Google translate